ByteDance completes $290M fundraising for AI drug unit

ByteDance: ByteDance is a Chinese multinational technology company that operates popular short-video platforms including TikTok and Douyin while expanding into artificial intelligence research and applications. The company has incubated AI initiatives across scientific domains and recently spun off its AI drug discovery operations into an independent entity to align with sector-specific development needs. This move positions ByteDance to retain strategic involvement while enabling focused growth in biotech applications of AI. Spin-off Rationale: ByteDance separated its AI drug discovery unit because pharmaceutical development follows different industry logic and management approaches than its core social media and internet operations. AI Drug Discovery Focus: The newly independent unit specializes in using artificial intelligence for end-to-end drug discovery, including structure prediction, protein design, and candidate development.